Large-scale study mapping the genetics of brain activity reveals shared and unique traits across different types of Parkinsonism

Researchers at the University of Bergen in Norway have completed one of the most comprehensive studies ever conducted on the genetics of Parkinsonism. By looking at how genes behave in nearly 1,000 brain samples, the team has created a detailed map that shows why different conditions can look similar but behave differently deep inside the brain. Mapping the blueprint of the brain The research focused on transcriptomics, which is the study of how our genetic instructions are actually put into action. Think of your DNA as a library of blueprints; transcriptomics looks at which blueprints are currently being used to build or run the "factory" of the brain. Professor Charalampos Tzoulis and his team examined samples from people who had several different conditions, including Parkinson’s, Dementia with Lewy bodies, Multiple System Atrophy (MSA), and Progressive Supranuclear Palsy (PSP). They compared these to healthy brains and those with Alzheimer’s to find the common threads and the unique differences. Shared struggles in brain cells The team discovered that all these conditions share a "core" set of problems. In every case, the brain’s ability to produce energy, repair its own DNA, and process proteins was significantly weakened. This suggests that while the visible symptoms might differ, the fundamental breakdown of how cells maintain themselves is very similar across the board. They also found that in all these conditions, the number of active neurons decreased while the activity of glial cells—which act as the brain's support and immune system—increased. This confirms that the brain is actively trying to respond to the damage caused by the condition. Key differences between conditions While there is a lot of overlap, the study also found important differences. Conditions like Parkinson’s and Dementia with Lewy bodies grouped together because they share similar genetic activity patterns. On the other hand, conditions like PSP showed a different "signature." Interestingly, Multiple System Atrophy (MSA) sat somewhere in the middle. It shared some traits with Parkinson’s but also had its own unique molecular markers. These differences are vital because they help explain why a treatment that works for one person might not work for someone with a slightly different form of the condition. A new tool for the future To help other scientists around the world, the researchers have turned their findings into an open-access web resource called ParkDB. This allows any researcher to look up a specific gene and see how it behaves across all these different conditions. By identifying these shared and unique pathways, the study provides a massive list of potential targets for new drugs. Instead of guessing which genes to focus on, scientists now have a clear map to guide them toward treatments that could one day slow down or stop the progression of these conditions.